IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v18y2017i6d10.1007_s10198-016-0857-3.html
   My bibliography  Save this article

The enigma of value: in search of affordable and accessible health care

Author

Listed:
  • Thomas D. Szucs

    (University of Basel)

  • Martina Weiss

    (Postfach)

  • Guido Klaus

    (Postfach)

Abstract

In times of shrinking resources and pharmaceutical breakthrough situations, our value-assessing systems are stretched to their very limits. Assessing value is highly complex. Current value-assessment systems risk neglecting important factors, such as therapy duration, budget impact, or the importance of combination therapies. Especially when dealing with breakthrough therapies within high-prevalence indications, these factors play an important role in health care spending. When it comes to assessing value in Switzerland, the system is innovation and access-friendly; the price level of pharmaceutical products, however, is relatively high in comparison to neighboring countries. The Swiss pricing and reimbursement system can still improve in terms of efficiency and transparency.

Suggested Citation

  • Thomas D. Szucs & Martina Weiss & Guido Klaus, 2017. "The enigma of value: in search of affordable and accessible health care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(6), pages 667-670, July.
    • Handle: RePEc:spr:eujhec:v:18:y:2017:i:6:d:10.1007_s10198-016-0857-3
    DOI: 10.1007/s10198-016-0857-3
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-016-0857-3
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-016-0857-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Valérie Paris & Elizabeth Docteur, 2007. "Pharmaceutical Pricing and Reimbursement Policies in Switzerland," OECD Health Working Papers 27, OECD Publishing.
    2. Pierre Moïse & Elizabeth Docteur, 2007. "Pharmaceutical Pricing and Reimbursement Policies in Sweden," OECD Health Working Papers 28, OECD Publishing.
    3. Nicod, Elena & Kanavos, Panos, 2012. "Commonalities and differences in HTA outcomes: A comparative analysis of five countries and implications for coverage decisions," Health Policy, Elsevier, vol. 108(2), pages 167-177.
    4. Pierre Moïse & Elizabeth Docteur, 2007. "Pharmaceutical Pricing and Reimbursement Policies in Mexico," OECD Health Working Papers 25, OECD Publishing.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Löblová, Olga & Csanádi, Marcell & Ozierański, Piotr & Kaló, Zoltán & King, Lawrence & McKee, Martin, 2019. "Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology," Health Policy, Elsevier, vol. 123(7), pages 630-634.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Charalabos-Markos Dintsios & Nadja Chernyak, 2022. "How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?," Applied Health Economics and Health Policy, Springer, vol. 20(3), pages 287-290, May.
    2. Melanie Levy, 2022. "The rise of the Swiss regulatory healthcare state: On preserving the just in the quest for the better (or less expensive?)," Regulation & Governance, John Wiley & Sons, vol. 16(2), pages 427-447, April.
    3. Lianne Barnieh & Fiona Clement & Anthony Harris & Marja Blom & Cam Donaldson & Scott Klarenbach & Don Husereau & Diane Lorenzetti & Braden Manns, 2014. "A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-10, March.
    4. Nazila Yousefi & Mahyar Polroudi Moghaddam & Gita Afsharmanesh & Farzad Peiravian, 2020. "Evaluation of efficiency enhancement in Iran Health Insurance Organization: a policy brief for pharmaceutical cost containment," International Journal of Health Planning and Management, Wiley Blackwell, vol. 35(6), pages 1503-1511, November.
    5. Kanavos, Panos, 2014. "Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States," Health Policy, Elsevier, vol. 118(2), pages 229-241.
    6. Frank R. Lichtenberg, 2022. "The association between pharmaceutical innovation and both premature mortality and hospital utilization in Switzerland, 1996–2019," Swiss Journal of Economics and Statistics, Springer;Swiss Society of Economics and Statistics, vol. 158(1), pages 1-24, December.
    7. Visintin, Erica & Tinelli, Michela & Kanavos, Panos, 2019. "Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries," Health Policy, Elsevier, vol. 123(2), pages 118-129.
    8. Kanavos, Panos & Visintin, Erica & Gentilini, Arianna, 2023. "Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries," Social Science & Medicine, Elsevier, vol. 331(C).
    9. Grepstad, Mari & Kanavos, Panos, 2015. "A comparative analysis of coverage decisions for outpatient pharmaceuticals: Evidence from Denmark, Norway and Sweden," Health Policy, Elsevier, vol. 119(2), pages 203-211.
    10. Serra-Sastre, Victoria & Bianchi, Simona & Mestre-Ferrandiz, Jorge & O’Neill, Phill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," LSE Research Online Documents on Economics 113639, London School of Economics and Political Science, LSE Library.
    11. Kanavos, Panos, 2019. "Does external reference pricing deliver what it promises? Evidence on its impact at national level," LSE Research Online Documents on Economics 101522, London School of Economics and Political Science, LSE Library.
    12. Elena Nicod, 2017. "Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four Europ," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(6), pages 715-730, July.
    13. Reisinger, Markus & Saurí, Lluís & Zenger, Hans, 2019. "Parallel imports, price controls, and innovation," Journal of Health Economics, Elsevier, vol. 66(C), pages 163-179.
    14. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
    15. Jennifer M Manne & Callae S Snively & Janine M Ramsey & Marco Ocampo Salgado & Till Bärnighausen & Michael R Reich, 2013. "Barriers to Treatment Access for Chagas Disease in Mexico," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 7(10), pages 1-10, October.
    16. Pepijn Vemer & Maureen Rutten-van Mölken, 2011. "Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(5), pages 397-404, October.
    17. Jürgen Maurer, 2007. "Assessing Horizontal Equity in Medication Treatment Among Elderly Mexicans: Which Socioeconomic Determinants Matter Most?," MEA discussion paper series 07143, Munich Center for the Economics of Aging (MEA) at the Max Planck Institute for Social Law and Social Policy.
    18. Mills, Mackenzie & Kanavos, Panos, 2022. "How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada," Health Policy, Elsevier, vol. 126(11), pages 1130-1143.
    19. Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
    20. Salas-Vega, Sebastian & Bertling, Annika & Mossialos, Elias, 2016. "A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK," Health Policy, Elsevier, vol. 120(10), pages 1104-1114.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:18:y:2017:i:6:d:10.1007_s10198-016-0857-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.